Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Conditions
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
pre-operative, endocrine treatment, drug resistance
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Intervention
Name: Anastrozole Type: Drug
Name: Anastrozole+Fulvestrant Type: Drug
Name: Tamoxifen Type: Drug
Name: Tamoxifen Type: Drug
Overall Status
Recruiting
Summary
To investigate prospectively whether short term endocrine treatment can induce molecular changes, predictive for therapy response.
Detailed Description
We will perform a randomized, open-label, single-institution study. It will compare the efficacy of three different endocrine treatment regimens (Anastrozole +/- Fulvestrant or Tamoxifen) in changing proliferation-index and inducing apoptosis during a 2-6 week pre-operative treatment period in breast cancer patients. These results will be correlated to gene expression profiles, phosphorylation status of the ER, SNPs in CYP450 sequences, tamoxifen metabolite concentrations, changes in estrogen serum levels and protein expression patterns.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- Patients with proven invasive adenocarcinoma of the breast

- Any tumor with a size ≥ 1cm (NOT inflammatory breast cancer)

- WHO-performance score 0 or 1

- Written informed consent

Exclusion Criteria:

- Clues of metastatic disease by clinical examination according to most recent NABON guidelines

- Multicentric breast cancer

- Inflammatory breast cancer

- Hormone replacement during the last 12 months

- Other systemic treatment during the waiting time till surgery

- Already planned date for surgery within the next 2 weeks

- Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol

- Patient's refusal to undergo a core biopsy procedure of the primary tumor before the start of treatment

NB: a concomitant malignancy within the last five years is not an exclusion criterium, because survival is not the primary endpoint. Just as prior invasive breast cancer or DCIS within the last 15 years is not an exclusion criterium.

NB: Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during the study.
Locations
NKI-AVL
Amsterdam, Netherlands
Status: Recruiting
Contact: Sabine C Linn, MD - +31-20-5129111 - s.linn@nki.nl
St. Antonius ziekenhuis
Nieuwegein, Netherlands
Status: Not yet recruiting
Contact: Paul C de Jong, MD
UMC St. Radboud
Nijmegen, Netherlands
Status: Recruiting
Contact: Hanneke W.M. Laarhoven, MD
Start Date
July 2008
Completion Date
June 2018
Sponsors
The Netherlands Cancer Institute
Source
The Netherlands Cancer Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page